Bruno C. Medeiros, MD, on AML: Targeted Treatment

2017 NCCN Hematologic Malignancies Congress
Tweet this page

Bruno C. Medeiros, MD, of Stanford Cancer Institute, discusses emerging novel agents and targeted molecular abnormalities in the management of acute myeloid leukemia.

Advertisement

Advertisement



Advertisement